MELA Sciences to Report Second Quarter 2014 Financial Results on Wednesday, August 13

IRVINGTON, N.Y., Aug. 4, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, will release second quarter 2014 financial results on Wednesday, August 13, after the market close. MELA Sciences President and Chief Executive Officer, Rose Crane, and Chief Financial Officer, Robert Cook, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.

Conference Call Details:
Date: Wednesday, August 13, 2014
Time: 4:30 p.m. Eastern Time
Toll Free: 800-274-0251
International: 719-325-2284
Passcode: 2866769
Replays, Available through August 29:
Toll Free: 877-870-5176
International: 858-384-5517
Replay PIN: 2866769

About MELA Sciences, Inc.

MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technology for the clinical early detection and prevention of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature.

CONTACT: Media Diana Garcia Redruello MELA Sciences, Inc. 212-518-4226 Investors Andrew McDonald LifeSci Advisors, LLC 646-597-6987 Andrew@LifeSciAdvisors.comSource:MELA Sciences